Propofol:

Intravenous, gamma-aminobutyric acid (GABA) receptor agonist and N-methyl-D-aspartate (NMDA) receptor antagonist

ECMO Dose Adjustment:

YES—an increased dose may be warranted in some patients.

Renal Impairment Dose Adjustment:

NONE

CRRT Dose Adjustment:

NONE

Hepatic Impairment Dose Adjustment:

NONE

Adult Starting Dose^:

Adult Continuous Infusion: 5-10 mcg/kg/min

Pediatric Starting Dose^:

Pediatric Continuous Infusion: 10-15 mcg/kg/min

Neonatal Starting Dose^:

Neonatal Continuous Infusion: 10-15 mcg/kg/min

^Always use the lowest effect dose to an objective endpoint (e.g., sedation scale).

Intravenous sedative physicochemical and pharmacokinetic characteristics

Drug	Propofol


Onset (min)	1-2
Log P	3.8
Protein Binding (%)	95-99
Metabolism / Elimination	Hepatic
Dose Adjustment on ECMO	+++
Dose Range*	Adult: 5-80 mcg/kg/min
	Pediatric: 10-80 mcg/kg/min
	Neonatal: 10-80 mcg/kg/min

- Minimal sequestration; no need for Dose Adjustment

++ Moderate sequestration; may require Dose Adjustment

+++ Significant sequestration; need for Dose Adjustment

*Titrate to patient-specific goals, using the lowest effective dose. Dose ranges represent doses typically used in clinical practice; in some situations, patients may require doses above the usual dose range to achieve patient-specific goals.